Lilly shares fall as company abandons evacetrapib development
October 13, 2015Manufacturing and Production evacetrapib, high cholesterol, lilly, phase III, phase III failure
Eli Lilly shares fell by nearly 8% this week as the company announced it will abandon developmenty of the investigational …
Blow for Scottish women as SMC rejects Afinitor for advanced breast cancer
October 12, 2015Sales and Marketing SMC, advanced breast cancer
The Scottish Medicines Consortium (SMC) has announced that it will not recommend Novartis’s Afinitor (everolimus) for use in advanced breast …
New cancer medicines approved in Scotland, available via NHS
October 12, 2015Sales and Marketing Scottish Medicines Consortium, Zytiga, abiraterone acetate, prostate cancer
The Scottish Medicines Consortium (SMC) has today recommended Janssen’s Zytiga (abiraterone acetate) for use before chemotherapy in men with advanced …
Health professionals back transparency of their dealings with pharma
October 12, 2015Research and Development, Sales and Marketing ABPI, transparency
The majority of doctors, nurses, hospital specialists and pharmacists believe that payments received by healthcare professionals (HCPs) from pharmaceutical companies …
Time for pharma to think big on genomics research
October 12, 2015Research and Development Sir John Chisholm, genomics
Sir John Chisholm, executive chair of Genomics England, is very clear about what the project he is overseeing is – …
Obama’s FDA nominee criticised for big pharma ties
October 12, 2015Sales and Marketing Bernie Sanders, Dr Robert Califf, FDA
Democratic presidential nomination candidate Senator Bernie Sanders has criticised President Obama’s choice for the next FDA commissioner, as a result …
Pfizer wins Zoloft birth defects lawsuit
October 12, 2015Sales and Marketing Pfizer, Zoloft, birth defects, lawsuits, sertraline
Judges in the US have dismissed a lawsuit against Pfizer that had claimed that the use of its antidepressant Zoloft during pregnancy …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
Novartis psoriasis drug shows three-year efficacy
October 12, 2015Cosentyx, EADV, Novartis, Secukinumab, psoriasis
Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …
How can pharma succeed in emerging markets?
October 10, 2015Sales and Marketing GSK, Pfizer
In recent years, the major pharma companies have been forced to react to the maturation and cost-cutting, plus regulatory pressures, …
Biogen reports on Tecfidera multiple sclerosis clinical trials
October 9, 2015Research and Development
Biogen has presented data demonstrating the efficacy and safety of Tecfidera (dimethyl fumarate) across a broad range of people with …
Almirall presents new data on cannabinoid-based MS treatment
October 9, 2015Research and Development Almirall, multiple sclerosis
Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …
EMA appoints Guido Rasi as executive director
October 9, 2015Medical Communications, Sales and Marketing EMA, Guido Rasi
The European Medicines Agency’s (EMA’s) Management Board has nominated Professor Guido Rasi as the Executive Director of the Agency. The …
Oncology groups and doctors fight for lower-priced cancer treatments
October 9, 2015Medical Communications, Research and Development, Sales and Marketing
Oncology groups such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) are working …
Sanofi looks to increase productivity in France by 25%
October 9, 2015Manufacturing and Production, Medical Communications Sanofi
Sanofi is looking for a deal with unions in order to boost productivity by 20-25% at French plants over three …
Merck announces positive Elbasvir/Grazoprevir trial results
October 9, 2015Research and Development
Merck has announced the publication of results from C-SURFER, the first Phase III clinical trial to investigate an all-oral, ribavirin-free …
AstraZeneca’s Moventig now available through NHS
October 9, 2015Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig
AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …
Taking on IFP, COPD and severe asthma: ERS 2015 roundup
October 9, 2015Medical Communications, Research and Development
Leading pharmaceutical companies, physicians, healthcare professionals, scientists, respiratory experts, and of course the media, including Pharmafocus, gathered in Amsterdam at the …
Ovid Therapeutics appoints Dr Jerome B. Zeldis to Its Scientific Advisory Board
October 9, 2015Medical Communications
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has …
Positive late-stage results for Genentech’s ocrelizumab in different forms of MS
October 8, 2015Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab
Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
